Targeting Glutaminase Isoforms for Therapy-Resistant Prostate Cancer
Abstract
Our preliminary study demonstrates that advanced prostate cancer is addicted to glutamine, and a glutaminase isoform switch contributes to the development of therapy resistance and disease progression. The major goal of the project was to study the molecular mechanisms of GLS1 isoform switch and explore the possibility of targeting glutamine metabolism as a novel therapeutic approach. In year 1, we have made the following Key Research Accomplishments: 1. We have verified a general phenomenon that ADT decreases the metabolic rate to suppress tumor growth. That is for the first time demonstrating how hormonal therapy works initially from a metabolic basis. 2. With powerful evidence delivered from accomplished tasks, we have also raised a high possibility for the therapeutic failure which could be that in addition to reduction of the majority of metabolites, hormonal therapy accumulates glutamine at the same time. This restored glutamine replaces androgen to become the crucial energy and nutrient source.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1124324
Entities
People
- Jiaoti Huang
Organizations
- Duke University